<div class="headers"><div>Supplementary Figure 2. Change in A1C from baseline to Week 52 by baseline A1C subgroup.*LS, least squares; SE, standard error; SITA, sitagliptin; CANA, canagliflozin.
*A1C <8.0%: SITA 100 mg (n = 174), CANA 300 mg (n = 185); A1C >8.0 to <9.0%: SITA 100 mg (n = 122), CANA 300 mg (n = 125); A1C >9.0%: SITA 100 mg (n = 82), CANA 300 mg (n = 67).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">Supplementary Figure 2. Change in A1C from baseline to Week 52 by baseline A1C subgroup.*</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">LS, least squares; SE, standard error; SITA, sitagliptin; CANA, canagliflozin.
*A1C <8.0%: SITA 100 mg (n = 174), CANA 300 mg (n = 185); A1C >8.0 to <9.0%: SITA 100 mg (n = 122), CANA 300 mg (n = 125); A1C >9.0%: SITA 100 mg (n = 82), CANA 300 mg (n = 67).</p></td>
</tr>
</tbody>
</table>
